544611 MAHALIFE

Mahamaya Lifesciences Share Price

 

 

Start SIP in MAHALIFE

Start SIP
Mahamaya Lifesciences live price: ₹155.4. It opened at ₹155 vs previous close ₹148; intraday high/low: ₹155/₹155. The 50 DMA stands at ₹160.77.

Mahamaya Lifesciences Performance

  • Today's Low
  • ₹155
  • Today's High
  • ₹155
  • 52 Week Low
  • ₹111
  • 52 Week High
  • ₹205
  • Open Price₹155
  • Previous Close₹148
  • Volume123,600
  • 50 DMA₹160.77
  • 100 DMA-
  • 200 DMA-

Investment Returns

  • Over 1 Month -0.42%
  • Over 3 Month -15.64%

Smart Investing Starts Here Start SIP with Mahamaya Lifesciences for Steady Growth!

Invest Now

Mahamaya Lifesciences Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 28.1
  • PEG Ratio
  • -
  • Market Cap Cr
  • 364
  • P/B Ratio
  • 5.7
  • Average True Range
  • 7.29
  • EPS
  • -
  • Dividend Yield
  • 0
  • MACD Signal
  • -7.68
  • RSI
  • 48.46
  • MFI
  • 70.79

Mahamaya Lifesciences Financials

Mahamaya Lifesciences Technicals

EMA & SMA

Current Price
₹155.40
+ 7.4 (5%)
pointer
  • Bearish Moving Average 4
  • Bullish Moving Average 7
  • 20 Day
  • ₹154.08
  • 50 Day
  • ₹160.77
  • 100 Day
  • -
  • 200 Day
  • -

Resistance and Support

155.38 Pivot Speed
  • R3 155.47
  • R2 155.43
  • R1 155.42
  • S1 155.37
  • S2 155.33
  • S3 155.32

Mahamaya Lifesciences Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-12-02 Half Yearly Results

Mahamaya Lifesciences F&O

Mahamaya Lifesciences Shareholding Pattern

56.35%
0.95%
6.39%
12.72%
23.59%

Mahamaya Lifesciences FAQs

Mahamaya Lifesciences share price is ₹155 As on 28 March, 2026 | 08:01

The Market Cap of Mahamaya Lifesciences is ₹363.7 Cr As on 28 March, 2026 | 08:01

The P/E ratio of Mahamaya Lifesciences is 28.1 As on 28 March, 2026 | 08:01

The PB ratio of Mahamaya Lifesciences is 5.7 As on 28 March, 2026 | 08:01

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23